

Levoleucovorin products (Fusilev, Khapzory)



Pharmacy Coverage Policy

Effective Date: January 01, 2023

Revision Date: January 01, 2023

Page: 1 of 6

Review Date: September 22, 2022

Line of Business: Medicaid - Louisiana

Policy Type: Prior Authorization

Humana's documents are updated regularly online. When printed, the version of this document becomes uncontrolled. Do not rely on printed copies for the most up-to date version. Refer to http://apps.humana.com/tad/tad_new/home.aspx to verify that this is the current version before utilizing.

Disclaimer Description Coverage Determination

Background Medical Terms References

Disclaimer

State and federal law, as well as contract language, including definitions and specific inclusions/exclusions, take precedence over clinical policy and must be considered first in determining eligibility for coverage. Coverage may also differ for our Medicare and/or Medicaid members based on any applicable Centers for Medicare & Medicaid Services (CMS) coverage statements including National Coverage Determinations (NCD), Local Medical Review Policies (LMRP) and/or Local Coverage Determinations. See the CMS website at <http://www.cms.hhs.gov/>. The member's health plan benefits in effect on the date services are rendered must be used. Clinical policy is not intended to pre-empt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Clinical technology is constantly evolving, and we reserve the right to review and update this policy periodically. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any shape or form or by any means, electronic, mechanical, photocopying or otherwise without permission from Humana.

Description

Levoleucovorin is the pharmacologically active isomer of leucovorin [(6-S)-leucovorin]. Fusilev (levoleucovorin) for injection contains levo-leucovorin calcium; Khapzory (levoleucovorin) contains sodium, chemically reduced derivatives of folic acid. It is useful as antidote to the inhibition of dihydrofolate reductase by methotrexate.

Lvoleucovorin is indicated for rescue after high-dose methotrexate therapy in osteosarcoma, diminishing the toxicity and counteracting the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists, and use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer. Limitations of use include the treatment of pernicious anemia and megaloblastic anemias secondary to the lack of vitamin B₁₂. Improper use may cause a hematologic remission while neurologic manifestations continue to progress.

Levoleucovorin is available as sterile solution in single-use vials as Fusilev 50 mg, 175 mg, and 250 mg for intravenous (IV) use only or single-dose vial as Khapzory 175 mg and 300 mg lyophilized powder.

Coverage

Please note the following regarding medically accepted indications:

Page: 2 of 6

Humana's documents are updated regularly online. When printed, the version of this document becomes uncontrolled. Do not rely on printed copies for the most up-to-date version. Refer to http://apps.humana.com/tad/tad_new/home.aspx to verify that this is the current version before utilizing.

Determination

All reasonable efforts have been made to ensure consideration of medically accepted indications in this policy. Medically accepted indications are defined by CMS as those uses of a covered Part D drug that are approved under the federal Food, Drug and Cosmetic Act, or the use of which is supported by one or more citations included or approved for inclusion in any of the compendia described in section 1927(g)(1)(B)(i) of the Act. These compendia guide review of off-label and off-evidence prescribing and are subject to minimum evidence standards for each compendium. Currently, this review includes the following references when applicable and may be subject to change per CMS:

- American Hospital Formulary Service-Drug Information (AHFS-DI)
- National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium
- Truven Health Analytics Micromedex DrugDEX
- Elsevier/Gold Standard Clinical Pharmacology
- Wolters Kluwer Lexi-Drugs

Fusilev (levoleucovorin), Khapzory (levoleucovorin) will require prior authorization. This agent may be considered medically necessary when the following criteria are met:

Osteosarcoma

- The member is being treated with high dose methotrexate for osteosarcoma AND
- The member has been treated with leucovorin calcium AND (one of the following applies):
 - member has experienced documented side effects due to lack of
 - leucovorin calcium efficacy OR member has experienced documented side effects due to leucovorin calcium formulation necessitating a change in therapy

See the [DISCLAIMER](#). All Humana member health plan contracts are NOT the same. All legislation/regulations on this subject

Impaired methotrexate elimination or inadvertent over dosage of folic acid antagonists

Page: 3 of 6

Humana's documents are updated regularly online. When printed, the version of this document becomes uncontrolled. Do not rely on printed copies for the most up-to date version. Refer to http://apps.humana.com/tad/tad_new/home.aspx to verify that this is the current version before utilizing.

- The member has been treated with methotrexate or other folic acid antagonist and is currently exhibiting signs of toxicity likely due to aforementioned therapy AND
- The member has been treated with leucovorin calcium AND (one of the following applies):
 - member has experienced documented side effects due to lack of leucovorin calcium efficacy OR member has experienced documented side
 - effects due to leucovorin calcium formulation necessitating a change in therapy

Advanced Metastatic Colorectal Cancer

- The member has advanced metastatic colorectal cancer AND
- The member is receiving palliative treatment with combination chemotherapy with 5-fluorouracil AND
- The member has been treated with leucovorin calcium AND (one of the following applies):
 - member has experienced documented side effects due to lack of leucovorin calcium efficacy OR member has experienced documented side
 - effects due to leucovorin calcium formulation necessitating a change in therapy

The recommended dosing regimen for Fusilev (levoleucovorin), Khapzory (levoleucovorin):

Levoleucovorin Rescue After High-Dose Methotrexate Therapy:

Levoleucovorin rescue recommendations are based on a methotrexate dose of 12 grams/m² administered by intravenous infusion over four hours. Levoleucovorin

See the [DISCLAIMER](#). All Humana member health plan contracts are NOT the same. All legislation/regulations on this subject

rescue at a dose of 7.5 mg (approximately 5 mg/m²) every six hours for ten doses starts 24 hours after the beginning of the methotrexate infusion. Levoleucovorin dose and/or frequency may need to be adjusted.

Page: 4 of 6

Humana's documents are updated regularly online. When printed, the version of this document becomes uncontrolled. Do not rely on printed copies for the most up-to-date version. Refer to http://apps.humana.com/tad/tad_new/home.aspx to verify that this is the current version before utilizing.

levoleucovorin administration in Combination with 5-Fluorouracil (5-FU): The following regimens have been used historically for the treatment of colorectal cancer:

- levoleucovorin administered at 100 mg/m² by slow intravenous injection over a minimum of 3 minutes, followed by 5-FU at 370 mg/m² by intravenous injection.
- levoleucovorin is administered at 10 mg/m² by intravenous injection followed by 5-FU at 425 mg/m² by intravenous injection.

Treatment is repeated daily for five days. This five-day treatment course may be repeated at 4 weeks (28-day) intervals, for 2 courses and then repeated at 4 to 5 week (28 to 35 day) intervals provided that the patient has completely recovered from the toxic effects of the prior treatment course.

- 5-FU and levoleucovorin should be administered separately to avoid the formation of a precipitate.
- Alternative dosing: Levoleucovorin, when substituted in place of leucovorin calcium within a chemotherapy regimen, is dosed at one-half the usual dose of leucovorin calcium

Do not administer intrathecally.

levoleucovorin is dosed at one-half the usual dose of the racemic form (leucovorin calcium).

Fusilev (levoleucovorin), Khapzory (levoleucovorin) will be approved for six-month durations or as determined through clinical review.

Levoleucovorin products (Fusilev, Khapzory)

Effective Date: 1/1/2023

Revision Date: 1/1/2023

Review Date: 9/22/2022

Line of Business: Medicaid - Louisiana

Policy Type: Prior Authorization

Coverage Limitations

Fusilev, Khapzory (levoleucovorin) therapy is not considered medically necessary for members with the following concomitant conditions:

- Members with pernicious anemia or megaloblastic anemia secondary to the lack of vitamin B₁₂

Page: 5 of 6

Humana's documents are updated regularly online. When printed, the version of this document becomes uncontrolled. Do not rely on printed copies for the most up-to date version. Refer to http://apps.humana.com/tad/tad_new/home.aspx to verify that this is the current version before utilizing.

- Experimental/Investigational Use – Indications not supported by CMS recognized compendia or acceptable peer reviewed literature.

Background

This is a prior authorization policy about Fusilev (levoleucovorin), Khapzory (levoleucovorin).

Dose Adjustments:

Clinical Situation	Laboratory Findings	Fusilev Dosage and Duration
Normal methotrexate elimination	Serum methotrexate level approximately 10 micromolar at 24 hours after start of administration, 1 micromolar methotrexate infusion) at 48 hours, and less than 0.2 micromolar at 72 hours	7.5 mg IV q 6 hours for 60 hours (10 doses starting at 24 hours after start of administration, 1 micromolar methotrexate infusion) at 48 hours, and less than 0.2 micromolar at 72 hours
Delayed late methotrexate elimination	Serum methotrexate level remaining above 0.2 micromolar at 72 hours, and more than 0.05 micromolar micromolar at 96 hours after administration	Continue 7.5 mg IV q 6 hours, until methotrexate level is less than 0.05 micromolar at 96 hours
Delayed early methotrexate until elimination and/or evidence is less of acute renal injury then 7.5	Serum methotrexate level of 50 micromolar or more than 24 hours, or 5 micromolar or more at 48 hours after administration, OR; a 100% increase in serum creatinine level at 24 hours after methotrexate administration (e.g., an increase 0.5 mg/dL to a level of 1 mg/dL or more)	75 mg IV q 3 hours until methotrexate level is less than 0.05 micromolar

levoleucovorin should not be utilized in the following:

See the [DISCLAIMER](#). All Humana member health plan contracts are NOT the same. All legislation/regulations on this subject

may not be included. This document is for informational purposes only.

Levoleucovorin products (Fusilev, Khapzory)

Effective Date: 1/1/2023

Revision Date: 1/1/2023

Review Date: 9/22/2022

Line of Business: Medicaid - Louisiana

Policy Type: Prior Authorization

- Hypersensitivity to folic acid, folinic acid/leucovorin, or mannitol.
- The safety and efficacy has not been established in pediatric patients less than six years old.

Page: 6 of 6

Humana's documents are updated regularly online. When printed, the version of this document becomes uncontrolled. Do not rely on printed copies for the most up-to-date version. Refer to http://apps.humana.com/tad/tad_new/home.aspx to verify that this is the current version before utilizing.

- Patients with pernicious anemia and megaloblastic anemias secondary to the lack of vitamin B₁₂. Improper use may cause a hematologic remission while neurologic manifestations continue to progress.
- Due to Ca⁺⁺ content in Fusilev, no more than 16 mL (160 mg) of levoleucovorin solution should be injected intravenously per minute.
- levoleucovorin may enhance the toxicity of fluorouracil.
- Concomitant use of d,l-leucovorin with trimethoprim-sulfamethoxazole for Pneumocystis carinii pneumonia in HIV patients was associated with increased rates of treatment failure in a placebo-controlled study.
- Fusilev (levoleucovorin) may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible members.
- Do not administer intrathecally.
- See also Coverage Limitations section of this policy.

Provider Claims Codes

For medically billed requests, please visit www.humana.com/PAL. Select applicable Preauthorization and Notification List(s) for medical and procedural coding information.

Medical Terms

Fusilev; levoleucovorin; prevention of methotrexate toxicity; folic acid antagonist overdose; colorectal cancer; intravenous; pharmacy; Khapzory

References

- Fusilev® (levoleucovorin calcium) [prescribing information]. Spectrum Pharmaceuticals, Inc. Irvine, CA. April 2011.
- National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics

See the [DISCLAIMER](#). All Humana member health plan contracts are NOT the same. All legislation/regulations on this subject

Levoleucovorin products (Fusilev, Khapzory)

Effective Date: 1/1/2023

Revision Date: 1/1/2023

Review Date: 9/22/2022

Line of Business: Medicaid - Louisiana

Policy Type: Prior Authorization

Compendium. update periodically

Khapzory (levoleucovorin calcium) [prescribing information]. Spectrum

Pharmaceuticals, Inc. Irvine, CA. October 2018.

See the [DISCLAIMER](#). All Humana member health plan contracts are NOT the same. All legislation/regulations on this subject

may not be included. This document is for informational purposes only.